TABLE 1

Concerns About Radioimmunotherapy for NHL According to Surveyed Population

ConcernMean rating ± SD
Oncologists and hematologists prefer to treat by themselves with nonradioactive compounds3.42 ± 1.49
131I-tositumomab or 90Y-ibritumomab tiuxetan treatment is too expensive3.41 ± 1.34
90Y-ibritumomab tiuxetan or 131I-tositumomab therapy provides poor payment for the time and effort in the administration process2.91 ± 1.53
90Y-ibritumomab tiuxetan or 131I-tositumomab therapy provides poor payment for the time and effort in the radiolabeling process2.51 ± 1.41
131I-tositumomab or 90Y-ibritumomab tiuxetan treatment does not have enough reported randomized studies2.49 ± 1.2
Most nuclear physicians are not trained to administer potential myeloablative therapies such as 90Y-ibritumomab tiuxetan or 131I-tositumomab2.48 ± 1.35
Concerns exist that subsequent treatments will not be possible after 131I-tositumomab or 90Y-ibritumomab tiuxetan administration2.47 ± 1.14
131I-tositumomab administration is too complicated2.46 ± 1.38
There might be unexpected late side effects of 131I-tositumomab or 90Y-ibritumomab tiuxetan treatment (myelodysplastic syndrome)2.36 ± 1.04
131I-tositumomab or 90Y-ibritumomab tiuxetan take too much time from my practice2.12 ± 1.21
We have concerns about the dosimetry procedure2.01 ± 1.17
We have concerns about radiation safety1.88 ± 1.11
90Y-ibritumomab tiuxetan administration is too complicated1.78363 ± 0.99
  • Thirteen factors are rated in decreasing order of concern.